Nazione: Canada
Lingua: inglese
Fonte: Health Canada
MYCOPHENOLATE MOFETIL
COBALT PHARMACEUTICALS COMPANY
L04AA06
MYCOPHENOLIC ACID
500MG
TABLET
MYCOPHENOLATE MOFETIL 500MG
ORAL
50/100
Prescription
IMMUNOSUPPRESSIVE AGENTS
Active ingredient group (AIG) number: 0128158002; AHFS:
CANCELLED POST MARKET
2018-05-07
_ _ _ _ _Page 1 of 55_ PRODUCT MONOGRAPH PR _CO_ MYCOPHENOLATE Mycophenolate Mofetil Tablets USP 500 mg Immunosuppressive Agent Cobalt Pharmaceuticals Company 6500 Kitimat Road Mississauga, Ontario L5N 2B8 SUBMISSION CONTROL NO: 168316 Date of Revision: October 16, 2013 _ _ _ _ _Page 2 of 55_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 7 DRUG INTERACTIONS ................................................................................................. 15 DOSAGE AND ADMINISTRATION ............................................................................. 18 OVERDOSAGE ............................................................................................................... 20 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 20 STORAGE AND STABILITY ......................................................................................... 27 SPECIAL HANDLING INSTRUCTIONS ...................................................................... 27 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 27 PART II: SCIENTIFIC INFORMATION .............................................................................. 28 PHARMACEUTICAL INFORMATION ......................................................................... 28 CLINICAL TRIALS ......................................................................................................... 29 DETAILED PHARMACOLOGY ............................................................................. Leggi il documento completo